Швајцарска - Италијански - Swissmedic (Swiss Agency for Therapeutic Products)

eli lilly (suisse) sa - tadalafilum - compresse rivestite con film - tadalafilum 20 mg, lactosum monohydricum 245.195 mg, hydroxypropylcellulosum, carmellosum natricum conexum, natrii laurilsulfas, cellulosum microcristallinum, magnesii stearas, pellicule: lactosum monohydricum 5.599 mg, hypromellosum, triacetinum, e 171, e 172 (flavum), e 172 (rubrum), talcum, pro compresso obducto corresp. natrium max. 2.09 mg. - ipertensione arteriosa polmonare - synthetika

Швајцарска - Италијански - Swissmedic (Swiss Agency for Therapeutic Products)

eli lilly (suisse) sa - insulinum glarginum - soluzione iniettabile - insulinum glarginum 3.64 mg corresp. insulinum glarginum 100 u., glycerolum, zinci oxidum, acidum hydrochloridum dilutum, natrii hydroxidum corresp. natrium 0.04 mg, metacresolum, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - il diabete mellito - biotechnologika

Швајцарска - Италијански - Swissmedic (Swiss Agency for Therapeutic Products)

eli lilly (suisse) sa - dulaglutidum - soluzione per iniezione penna pre-riempita monouso - dulaglutidum 1.5 mg, natrii citras dihydricus corresp. natrium 0.32 mg, acidum citricum, mannitolum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 0.5 ml. - antidiabétique, prévention d'événements cardiovasculaires - biotechnologika

Швајцарска - Италијански - Swissmedic (Swiss Agency for Therapeutic Products)

eli lilly (suisse) sa - dulaglutidum - soluzione per iniezione penna pre-riempita monouso - dulaglutidum 0.75 mg, natrii citras dihydricus corresp. natrium 0.32 mg, acidum citricum, mannitolum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 0.5 ml. - antidiabétique, prévention d'événements cardiovasculaires - biotechnologika

Швајцарска - Италијански - Swissmedic (Swiss Agency for Therapeutic Products)

eli lilly (suisse) sa - atomoxetinum - soluzione buvable - atomoxetinum 4 mg ut atomoxetini hydrochloridum, natrii dihydrogenophosphas dihydricus, acidum phosphoricum dilutum, sorbitolum liquidum cristallisabile corresp. sorbitolum 33 mg, xylitolum, aromatica (framboise), propylenglycolum 9.8 mg, sucralosum, natrii hydroxidum, e 211 0.8 mg, aqua purificata q.s. ad solutionem pro 1 ml corresp. natrium 2.64 mg. - tdah - synthetika

Швајцарска - Италијански - Swissmedic (Swiss Agency for Therapeutic Products)

eli lilly (suisse) sa - ixekizumabum - soluzione iniettabile en seringue préremplie - ixekizumabum 80 mg, saccharum, polysorbatum 80, natrii hydroxidum q.s. ad ph, aqua ad iniectabile, ad solutionem pro 1 ml. - psoriasis en plaques chez l'adulte, arthrite psoriasique, psoriasis en plaques chez l'enfant et l'adolescent à partir de 6 ans et d'un poids corporel d'au moins 25 kg, spondylarthrite ankylosante, spondyloarthrite axiale non radiographique - biotechnologika

Швајцарска - Италијански - Swissmedic (Swiss Agency for Therapeutic Products)

eli lilly (suisse) sa - ixekizumabum - soluzione per iniezione in pre-riempita penna - ixekizumabum 80 mg, saccharum, polysorbatum 80, natrii hydroxidum q.s. ad ph, aqua ad iniectabile, ad solutionem pro 1 ml. - psoriasis en plaques chez l'adulte, arthrite psoriasique, psoriasis en plaques chez l'enfant et l'adolescent à partir de 6 ans et d'un poids corporel d'au moins 25 kg, spondylarthrite ankylosante, spondyloarthrite axiale non radiographique - biotechnologika

Швајцарска - Италијански - Swissmedic (Swiss Agency for Therapeutic Products)

eli lilly (suisse) sa - baricitinibum - compresse rivestite con film - comprimé pelliculé: baricitinibum 2 mg, mannitolum 52 mg, cellulosum microcristallinum, carmellosum natricum conexum, magnesii stearas, pellicule: poly(alcohol vinylicus), macrogolum, talcum, lecithinum ex soja, e 171, e 172 (rubrum), pro compresso obducto, natrium 0.7608 mg. - polyarthrite rhumatoïde / dermatite atopique / covid 19 / alopecia areata - synthetika

Швајцарска - Италијански - Swissmedic (Swiss Agency for Therapeutic Products)

eli lilly (suisse) sa - baricitinibum - compresse rivestite con film - comprimé pelliculé: baricitinibum 4 mg, mannitolum 50 mg, cellulosum microcristallinum, carmellosum natricum conexum, magnesii stearas, pellicule: poly(alcohol vinylicus), macrogolum, talcum, lecithinum ex soja, color.: e 171, e 172 (rubrum), pro compresso obducto, natrium 0.7608 mg. - polyarthrite rhumatoïde / dermatite atopique / covid 19 / alopecia areata - synthetika

Европска Унија - Италијански - EMA (European Medicines Agency)

eli lilly nederland b.v. - abemaciclib - neoplasie al seno - agenti antineoplastici - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.